Alvotech (NASDAQ:ALVO) Sees Unusually-High Trading Volume – Should You Buy?

Alvotech (NASDAQ:ALVO) shares saw unusually-high trading volume on Monday . Approximately 731,636 shares changed hands during trading, an increase of 43% from the previous session’s volume of 511,028 shares.The stock last traded at $4.0380 and had previously closed at $3.54.

Wall Street Analysts Forecast Growth

ALVO has been the topic of a number of recent research reports. Wall Street Zen cut shares of Alvotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. Zacks Research raised shares of Alvotech from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 19th. Barclays reduced their target price on shares of Alvotech from $5.00 to $4.00 and set an “underweight” rating on the stock in a research report on Tuesday, March 24th. Weiss Ratings raised shares of Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Finally, UBS Group dropped their price target on shares of Alvotech from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.60.

Alvotech Stock Down 1.9%

The business’s 50 day moving average is $3.49 and its 200-day moving average is $4.26. The firm has a market cap of $1.26 billion, a P/E ratio of -16.64 and a beta of 0.21.

Alvotech (NASDAQ:ALVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.09) earnings per share (EPS) for the quarter. The company had revenue of $105.90 million during the quarter. Alvotech had a negative return on equity of 11.92% and a negative net margin of 14.36%. As a group, equities analysts predict that Alvotech will post 0.02 earnings per share for the current year.

Institutional Trading of Alvotech

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Alvotech by 2.7% during the third quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company’s stock valued at $35,481,000 after purchasing an additional 114,255 shares during the last quarter. Millennium Management LLC increased its stake in Alvotech by 1,707.7% during the fourth quarter. Millennium Management LLC now owns 357,176 shares of the company’s stock valued at $1,832,000 after purchasing an additional 337,417 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Alvotech by 88.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock valued at $1,331,000 after purchasing an additional 122,089 shares during the last quarter. Geode Capital Management LLC increased its stake in Alvotech by 10.7% during the fourth quarter. Geode Capital Management LLC now owns 254,921 shares of the company’s stock valued at $1,308,000 after purchasing an additional 24,667 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC bought a new stake in Alvotech during the second quarter valued at $1,782,000.

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).